LKQ (LKQ) FY 2025 Annual General Meeting May 07, 2025 03:00 PM ET Speaker0 I want to welcome all of you to the Annual Meeting of Stockholders of LKQ Corporation. I am Justin Jude, President and Chief Executive Officer of LKQ. We are pleased to be hosting our sixth virtual meeting. It is now shortly after 2PM Central on Wednesday, May 7, and this meeting is called to order. I would like to introduce the other members of the board participating in today's meeting, Patrick Burrard, Andrew Clark, Meg DeVito, Su ...

Terns Pharmaceuticals (TERN) 2025 Conference May 07, 2025 02:30 PM ET Speaker0 That seems silly. Exactly. Speaker1 It's crazy. You Speaker2 get dual, though. I mean, quite a bit. Alright. Speaker1 Are you ready? Speaker2 Yeah. Yeah. Speaker1 Alright. Then let's start. So welcome back to the Citizens Life Science Conference. My name is Silvan Turcan. I'm a senior analyst covering precision medicines. It's my pleasure to host TERM Pharmaceuticals. So, yeah, thanks so much for joining us. We got Scott Harris h ...

Lincoln Electric (LECO) FY Conference May 07, 2025 02:15 PM ET Speaker0 Good afternoon, everyone. Welcome to the twentieth annual Oppenheimer Industrial Growth Conference. Next up and and the last in the fireside chat lineup today, but certainly not least, we have the Lincoln Electric team represented by, CFO, Gabe Bruno. Gabe, thanks for joining us. Speaker1 Thanks for having us, Brian. Speaker0 Of course. Of course. To start things off, I guess, for for those a little newer to the WICO story, I think Linc ...

Speaker0 Douglas Emmett (DEI) Q1 2025 Earnings Call May 07, 2025 02:00 PM ET For a more detailed description of some potential risks, please refer to our SEC filings, which can be found in the Investor Relations section of our website. When we reach the question and answer portion, in consideration of others, please limit yourself to one question and one follow-up. I will now turn the call over to Jordan. Ladies and gentlemen, thank you for standing by. Welcome to Douglas Emmett's Quarterly Earnings Call. T ...

BuzzFeed (BZFD) Q1 2025 Earnings Call May 07, 2025 02:00 PM ET Speaker0 Good day, and welcome to BuzzFeed's First Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker, Vice President of Communications, Julianna Clifton. Please go ahead. Speaker1 Hi, everyone. Welcome to BuzzFeed Inc. First quarter twenty twenty five earnings confe ...

Unitil (UTL) Q1 2025 Earnings Call May 07, 2025 02:00 PM ET Speaker0 Good day and thank you for standing by. Welcome to the First Quarter twenty twenty five Unitil Earnings Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you will need to press 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, pleas ...

Summary of Adicet Bio (ACET) Conference Call Company Overview - Adicet Bio is a leader in gamma delta CAR T cell therapies, which have several advantages over traditional therapies, including being off-the-shelf, better safety profiles, and effective tissue distribution [3][4][5][6][7]. Key Advantages of Gamma Delta CAR T Cells - **Off-the-Shelf Availability**: Gamma delta CAR T cells can be administered without prior patient-specific modifications, reducing preparation time [3]. - **Safety Profile**: These cells are associated with lower rates of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) compared to alpha beta T cells [4]. - **Tissue Distribution**: Gamma delta T cells effectively localize to tissues, which is beneficial for treating autoimmune diseases and solid tumors [5][6]. - **Innate Antitumor Activity**: They can target tumor cells even if they do not express the specific target, enhancing their therapeutic potential [7]. Clinical Programs and Data - Adicet Bio is currently running two clinical programs and has two preclinical programs in development [8]. - In clinical trials for diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL), the complete response (CR) rates were comparable to autologous therapies, with a notable safety advantage [11][12]. - The company is focusing on autoimmune diseases, particularly lupus nephritis (LN) and systemic lupus erythematosus (SLE), with plans to expand to other conditions like systemic sclerosis and ANCA vasculitis [19][21]. Market Potential and Unmet Needs - The market for autoimmune diseases is significant, with high unmet medical needs, particularly in conditions like lupus nephritis, where patients face severe long-term health risks [25]. - The company aims to provide a one-time therapy that could lead to complete responses, reducing the need for ongoing immunosuppressants [25]. Data Expectations and Patient Selection - Investors are looking for data from at least six patients with three months of follow-up to assess efficacy [27]. - The ideal patient profile includes younger individuals with recent diagnoses and minimal existing tissue damage [31]. Competitive Landscape - The cell therapy space is competitive, with many companies pivoting from oncology to autoimmune diseases based on promising academic data [33]. - Adicet Bio differentiates itself by offering off-the-shelf therapies that do not require leukapheresis or personalized manufacturing, which can complicate treatment [36][39]. Future Developments - The company is also exploring renal cell carcinoma (RCC) as a new target, leveraging its unique advantages in tissue targeting and safety [44][46]. - Data from RCC trials is expected in the second half of the year, with a focus on achieving better outcomes than existing therapies [49]. Financial Position - Adicet Bio has approximately $150 million in cash, which is expected to fund operations into the second half of the following year [52]. - The company is open to business development opportunities to enhance its pipeline and financial stability [52]. Regulatory Environment - Interactions with regulatory agencies have been positive, with a collaborative approach noted in discussions about innovative therapies [53][54]. - The company believes that therapies demonstrating significant patient benefits will receive favorable attention from regulators [54]. Conclusion - Adicet Bio is positioned to make significant advancements in both autoimmune and oncology sectors with its gamma delta CAR T cell therapies, addressing critical unmet needs while navigating a competitive landscape and regulatory challenges [56].

Axsome Therapeutics (AXSM) 2025 Conference May 07, 2025 01:30 PM ET Speaker0 Started, so, thank you everybody for joining us again, this afternoon at the Citizens Life Science Conference. Really excited to be joined next by Axsome Therapeutics. Axsome is a commercial stage, company focused on, CNS indications. It actually has a number of approved products as well as a broad pipeline. As usual, a ton of stuff going on both from a regulatory perspective, data that you've read out in the couple months, as well ...

Clearside Biomedical (CLSD) 2025 Conference May 07, 2025 01:00 PM ET Speaker0 Welcome to day one of the Citizens Life Sciences Conference. My name is John Walden, senior analyst here. We're pleased to have Clearside Biomedical represented by CMO Victor Chong and CFO Charlie Dignan. So thanks for joining us guys. Thank you. So can you talk a little bit about the potential benefits and what you need to do to get more traction as Charlie mentioned there's been thousands of injections done but there's thousands ...

California Resources (CRC) Q1 2025 Earnings Call May 07, 2025 01:00 PM ET Speaker0 Good day, and welcome to the California Resources Corporation First Quarter twenty twenty five Conference Call. All participants will be in listen only mode. Please note this event is being recorded. I would now like to turn the conference over to Joanna Park, Vice President of Investor Relations and Treasurer. Please go ahead. Speaker1 Good morning, and welcome to California Resources Corporation's first quarter twenty twent ...